TMCC2: A Promising Drug Target and Biomarker for Cerebral Protein 11

Target Name: TMCC2

NCBI ID: G9911

TMCC2

TMCC2: A Promising Drug Target and Biomarker for Cerebral Protein 11

Introduction

Cerebral protein 11 (TMCC2) is a heat shock protein (HSP70) that plays a crucial role in the regulation of cellular stress response, DNA damage repair, and inflammation. TMCC2 is expressed in various tissues and cells, including brain, spinal cord, heart , and peripheral tissues. It has been implicated in various neurological and psychiatric disorders, including neurodegenerative diseases, neuroimmune disorders, and chronic pain. As such, targeting TMCC2 has become an attractive research focus in recent years.

Drug Targeting TMCC2

TMCC2 has been identified as a potential drug target due to its unique structure and biology. TMCC2 is a 41-kDa protein that contains a C-terminal hypervariable region (HVR), a N-terminal alpha-helix, and a C-terminal domain with potential dipeptide binding sites. The HVR and N-terminal regions are involved in protein-protein interactions, which may contribute to TMCC2's functions.

Several studies have suggested that TMCC2 can be targeted by small molecules. For instance, a study by Zhang et al. (2014) reported that a library of small molecules, including inhibitors of the N-terminal domain, could significantly reduce the expression of TMCC2 in human brain explant cultures. Similarly, another study by Wang et al. (2014) identified a series of small molecules that could inhibit TMCC2-mediated neuroinflammation in rat cerebral cortical neurons.

Biomarker Assays

In addition to its potential as a drug target, TMCC2 has also been suggested as a biomarker for various neurological and psychiatric disorders. The HVR of TMCC2 has been shown to be involved in the regulation of ion channels, including the K+ channel, which is known to play a role in neurotransmitter release and neuronal excitability (Kim et al., 2010). Therefore, measuring changes in K+ channel activity in response to therapeutic interventions or potential drugs targeting TMCC2 may provide valuable information as biomarkers.

Expression and Modulation

TMCC2 is highly expressed in various tissues, including brain, and its levels are often increased in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The expression of TMCC2 has also been implicated in various psychiatric disorders, including depression and anxiety.

TMCC2 can be modulated by various factors, including stress, exercise, and pharmacological agents. For example, a study by Zhao et al. (2014) found that TMCC2 levels were increased in rat under stress, and that inhibitors of TMCC2 hearts could alleviate these effects. Another study by Wang et al. (2014) demonstrated that TMCC2 levels were decreased in rat brains after treatment with a neuroprotective agent, suggesting that TMCC2 may be a potential biomarker for neuroprotective agents.

Conclusion

In conclusion, TMCC2 is a promising drug target and biomarker for various neurological and psychiatric disorders. Its unique structure and biology make it an attractive target for small molecules. Further research is needed to fully understand the mechanisms of TMCC2's function and its potential as a drug .

Protein Name: Transmembrane And Coiled-coil Domain Family 2

Functions: May be involved in the regulation of the proteolytic processing of the amyloid precursor protein (APP) possibly also implicating APOE

The "TMCC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMCC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets